Telix Pharmaceuticals is trading 4.19% up at A$15.91, with no confirmed catalyst identified for the gain.
- David Gill will become Chair effective September 1, 2026, succeeding interim Chair Mark Nelson.
- Available coverage does not explicitly link the appointment announcement to the September 2 gain.
- Biotech was down 4.24%, while broader risk-off conditions also do not clearly explain the positive move.